Sign In
Buy AZN
$176.43
+1.50 (+0.86%)
At Close: Jun 22, 2026
If you're looking for diversification and value, here's a good ETF to check out.
6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash
10:32am, Wednesday, 06'th May 2026
Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.
ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
02:56pm, Monday, 04'th May 2026
AbbVie ABBV stock has risen around 5% since it announced robust first-quarter 2026 results on April 29. It beat estimates for both earnings and sales and the guidance for 2026 revenues and earnings w
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat
08:45am, Saturday, 02'nd May 2026
Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong guidance—that could serve as a sorely
AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters
08:20am, Friday, 01'st May 2026
The U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) delivered mixed recommendations for AstraZeneca Plc (NASDAQ:AZN), endorsing its prostate cancer regimen while declinin
AstraZeneca stock falls after FDA panel votes against new cancer drug
05:51am, Friday, 01'st May 2026
An advisory panel for the U.S. Food and Drug Administration voted 6-3 against AstraZeneca's oral drug camizestrant intended for a type of breast cancer tumor, citing concerns around trial design. Astr
AstraZeneca falls as FDA advisers reject breast cancer drug use
05:46am, Friday, 01'st May 2026
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 1.9% to 13,688p after the US regulator's advisory panel declined to back its camizestrant treatment in a...
AstraZeneca falls as FDA advisers reject breast cancer drug use
05:01am, Friday, 01'st May 2026
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 1.9% to 13,688p after the US regulator's advisory panel declined to back its camizestrant treatment in a key breast cancer setting. The FTSE 100 drugm
AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote
03:56am, Friday, 01'st May 2026
The British pharmaceutical group said it would continue to work with U.S. regulators on a review of its breast-cancer candidate after the drug failed to get backing at a key advisory committee vote.
AstraZeneca shares drop after US regulatory panel votes against breast cancer drug
03:09am, Friday, 01'st May 2026
Shares of AstraZeneca fell 1.7% on Friday after an advisory panel for the U.S. Food and Drug Administration overnight voted against recommending the British drugmaker'
AstraZeneca Is a Buy as More Than 20 Phase III Readouts Loom
02:24pm, Thursday, 30'th Apr 2026
Our AstraZeneca (NASDAQ:AZN | AZN Price Prediction) call comes one day after the British drugmaker reported Q1 2026 revenue of $15.29 billion, up 13% year over year, and reaffirmed full-year guidance.
FDA panel votes against backing AstraZeneca's breast cancer drug
01:48pm, Thursday, 30'th Apr 2026
A panel of outside experts to the U.S. Food and Drug Administration voted against backing the risk-benefit profile of AstraZeneca's breast cancer drug, the company
Citi raises AstraZeneca earnings forecast and maintains 'buy' rating ahead of second-half pipeline catalysts
08:47am, Thursday, 30'th Apr 2026
Bank lifts 2026 core earnings per share estimate 2% to $10.30 after first-quarter beat, sees positive risk-reward into late-year readouts Citi has raised its 2026 core earnings per share forecast for
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca
07:00pm, Wednesday, 29'th Apr 2026
Option exercise triggers $25M payment to Pinetree. CAMBRIDGE, Mass.
AstraZeneca PLC (AZN) Q1 2026 Earnings Call Transcript
04:21pm, Wednesday, 29'th Apr 2026
AstraZeneca PLC (AZN) Q1 2026 Earnings Call Transcript
